o STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:51:47 ON 26 OCT 2009

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'CAPLUS' ENTERED AT 15:52:11 ON 26 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Oct 2009 VOL 151 ISS 18
FILE LAST UPDATED: 25 Oct 2009 (20091025/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s losartan
          6428 LOSARTAN
             1 LOSARTANS
L1        6428 LOSARTAN
                (LOSARTAN OR LOSARTANS)

=> s l1 and "polymorph"
          9711 "POLYMORPH"
         11139 "POLYMORPHS"
         16864 "POLYMORPH"
                ("POLYMORPH" OR "POLYMORPHS")
L2          18 L1 AND "POLYMORPH"

=> s l2 and composition
        765717 COMPOSITION
        353365 COMPOSITIONS
       1111104 COMPOSITION
                (COMPOSITION OR COMPOSITIONS)
       1650132 COMPN
        663056 COMPNS
       2018964 COMPN
                (COMPN OR COMPNS)
       2510483 COMPOSITION
                (COMPOSITION OR COMPN)
L3          8 L2 AND COMPOSITION

=> d l3 1-8 ibib ab

L3   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2009:835717  CAPLUS
DOCUMENT NUMBER:         151:221177
TITLE:                   Amino acid ester derivatives as antihypertensive
                         agents and their manufacture method, pharmaceutical
```

compositions and use in the treatment of
INVENTOR(S): Wang, Jianmin
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 43pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101475565	A	20090708	CN 2009-10076875	20090123
PRIORITY APPLN. INFO.:			CN 2009-10076875	20090123

OTHER SOURCE(S): MARPAT 151:221177
AB The invention relates to amino acid ester derivs. of formula I, which are antihypertensive agents. The uptake of the compds. is mediated by PepT1 transporter and decomposed to generate losartan, which play roles in the treatment process. Compds. of formula I wherein R1-R4 are independently H, (un)substituted (thio)alkyl, (un)substituted cycloalkyl, (un)substituted alkoxy, (un)substituted aryl, (un)substituted aralkyl; R1R2 may taken together with the atom attached to form (un)substituted cycloalkyl; R2R3 or R3R4 may take together with the atom attached to form (un)substituted heterocyclic group; and their pharmaceutically acceptable salts, solvates, polymorphs, enantiomers and racemates thereof, are claimed. Example compound II was prepared by amidation of N-Boc-L-asparagine with 2-butyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)-1,1'-biphen-4-yl]methylimidazole-5-methanol. All the invention compds. were evaluated for their antihypertensive activity. From the assay, it was determined that compound II exhibited the concentration of losartan in blood of 0.214 μM with the AUC of 209 μMhr.

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:454412 CAPLUS
DOCUMENT NUMBER: 150:447911
TITLE: Preparation of acetamide derivatives as glucokinase activators
INVENTOR(S): Bhuniya, Debanath; Sandeep, Bhausaheb Bhosale; Gobind, Sing Kapkoti; Venkata, Poornapragnacharyulu Palle; De, Siddhartha; Mookhtiar, Kasim A.
PATENT ASSIGNEE(S): Advinus Therapeutics Pvt., Ltd., India
SOURCE: PCT Int. Appl., 85pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009047798	A2	20090416	WO 2008-IN650	20081007
WO 2009047798	A3	20090604		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: IN 2007-CH2266 A 20071008

OTHER SOURCE(S): MARPAT 150:447911

AB Title compds. I [ring A and C independently = (un)substituted aryl, heteroaryl or heterocyclyl; ring B = (un)substituted 4 to 12-membered mono- or bicyclic heterocyclyl; X = O, NR6 or S(O)p; R1 = (un)substituted cycloalkyl or heterocyclyl; R2 = H; R3 = H, alkyl or perfluoroalkyl; R4 and R5 independently = H, halo, alkyl, alkenyl, etc.; R6 = H, alkyl, alkenyl, alkynyl, etc.; p = 0-2], and their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates or formulations, are prepared and disclosed. I and pharmaceutical compns. thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. Thus, e.g., II was prepared in general procedure. As glucokinase activators, II exhibited EC50 value of 0.13 μM in in vitro glucokinase assay.

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:761240 CAPLUS

DOCUMENT NUMBER: 147:166619

TITLE: Preparation of β-amino acid derivatives as dipeptidyl peptidase-IV inhibitors

INVENTOR(S): Sattigeri, Jitendra A.; Ahmed, Shahadat; Andappan, Murugaiah M. S.; Sethi, Sachin; Sharma, Lalima; Pal, Chanchal Kumar; Kandalkar, Sachin Ramesh; Mahajan, Dipak C.; Kishore, Kaushal; Bhatia, Sumati; Gadhave, Anil G.; Bansal, Vinay S.; Davis, Joseph Alexanand

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007077508	A2	20070712	WO 2006-IB55006	20061221
WO 2007077508	A3	20071025		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1973918	A2	20081001	EP 2006-842659	20061221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2008DN06231	A	20081024	IN 2008-DN6231	20080716
US 20090156465	A1	20090618	US 2009-159562	20090224
PRIORITY APPLN. INFO.:			IN 2005-DE3520 A	20051230
			WO 2006-IB55006 W	20061221

OTHER SOURCE(S): MARPAT 147:166619

AB The invention relates to the preparation of β-amino acid derivs. I [A = (hetero)aryl; E, E' = independently (CRaRb)n; n = 1-2; Ra, Rb = independently H, alk(en/yn)yl, cycloalkyl, (hetero)/aryl, heterocyclyl; RaCRb = optionally unsatd. ring; R = (un)substituted 2,5-diazabicyclo[2.2.1]hept-2-yl, (piperidin-4-yl)amino, -3-azabicyclo[3.1.0]hex-6-yl, etc.], and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, prodrugs, metabolites, and N-oxides, as dipeptidyl peptidase-IV inhibitors. This invention also relates to pharmacol. compns. containing the compds. of the invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurol., anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. I can also be used for treatment of infertility arising due to polycystic ovary syndrome. Thus, coupling 4-amino-1-[(morpholin-4-yl)carbonyl]piperidine tosylate with (3R)-3-[N-(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoic acid and cleavage of tert-butoxycarbonyl group in the presence of TFA gave II•TFA . I were evaluated for their peptidase-IV inhibitory activity using a fluorometric assay (IC50 values in the range of 1 nm to 10 μM).

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1004564 CAPLUS

DOCUMENT NUMBER: 143:292576

TITLE: Stabilization of a polymorphic form of losartan potassium

INVENTOR(S): Svete, Peter; Grahek, Rok; Humar, Vlasta; Husu-Kovacevic, Breda; Jerala-Strukelj, Zdenka

PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005084670	A1	20050915	WO 2005-EP2108	20050228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1729766	A1	20061213	EP 2005-707662	20050228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20070298108	A1	20071227	US 2007-590889	20070604
PRIORITY APPLN. INFO.:			SI 2004-67 A	20040301
			WO 2005-EP2108 W	20050228

AB Compns. were developed which stabilize an active pharmaceutical ingredient in polymorph form susceptible to degradation or interconversion into other polymorph forms, where stabilizing substance is conveniently among silicon dioxide, silicified microcryst. cellulose, magnesium oxide and polyethylene glycol. The polymorphic form of losartan potassium was stable when formulated with Syloid and PEG 6000.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:740288 CAPLUS

DOCUMENT NUMBER: 141:248753

TITLE: Preparation of losartan potassium polymorphs

INVENTOR(S): Boccignone, Andrea; Malpezzi, Luciana; Castaldi, Graziano; Allegrini, Pietro; Beltrame, Andrea

PATENT ASSIGNEE(S): Dinamite Dipharma S.P.A. In Abbreviate Form Dipharma S.P.A., Italy; Dipharma S.P.A.

SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076406	A2	20040910	WO 2004-EP1717	20040220
WO 2004076406	A3	20050113		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IT 2003-MI328 A 20030225

AB Losartan potassium polymorphs, identified as losartan potassium crystalline hydrate, losartan potassium amorphous and losartan potassium modification crystalline III, a process for their preparation, pharmaceutical compns. containing them and their use in therapy. Thus, losartan was dissolved in MeOh and treated with KHCO3 to give a losartan potassium polymorph III.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:610104 CAPLUS

DOCUMENT NUMBER: 141:134092

TITLE: Telmisartan–simvastatin combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases

INVENTOR(S): Riedel, Axel; Sendra, Josep-Maria; Leiter, Josef M. E.; Kauschke, Stefan; Mark, Michael

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg

SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062729	A1	20040729	WO 2004-EP175	20040114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA				
DE 10301372	A1	20040729	DE 2003-10301372	20030116
DE 10335027	A1	20050217	DE 2003-10335027	20030731
AU 2004204353	A1	20040729	AU 2004-204353	20040114
CA 2513281	A1	20040729	CA 2004-2513281	20040114
US 20040259925	A1	20041223	US 2004-757295	20040114
EP 1587584	A1	20051026	EP 2004-701918	20040114
EP 1587584	B1	20070523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006812	A	20051227	BR 2004-6812	20040114
JP 2006515877	T	20060608	JP 2006-500558	20040114
AU 2004260606	A1	20050210	AU 2004-260606	20040724
CA 2534006	A1	20050210	CA 2004-2534006	20040724
EP 1651213	A1	20060503	EP 2004-763484	20040724
EP 1651213	B1	20090923		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829511	A	20060906	CN 2004-80022096	20040724
BR 2004013165	A	20061003	BR 2004-13165	20040724
JP 2007500677	T	20070118	JP 2006-521497	20040724
NZ 544877	A	20090430	NZ 2004-544877	20040724
AT 443519	T	20091015	AT 2004-763484	20040724
MX 2005007559	A	20050921	MX 2005-7559	20050714
NO 2005003793	A	20050810	NO 2005-3793	20050810
ZA 2005009835	A	20061129	ZA 2005-9835	20051205
MX 2006001322	A	20060504	MX 2006-1322	20060131
KR 2006054404	A	20060522	KR 2006-702186	20060131
NO 2006000938	A	20060227	NO 2006-938	20060227

PRIORITY APPLN. INFO.:

DE 2003-10301372	A	20030116
DE 2003-10335027	A	20030731
DE 2003-10301371	A	20030116
US 2003-446695P	P	20030211
US 2003-503317P	P	20030916
DE 2003-10346260	A	20031006
DE 2003-10356815	A	20031205
WO 2004-EP175	W	20040114
WO 2004-EP8326	W	20040724

AB The invention discloses a method for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases, achieved by the improvement of endothelial function and the protection of organs, tissues and vessels when indications require a blood pressure check and a lipid level check, especially in patients that have been diagnosed with type 2 diabetes mellitus or if prediabetes is suspected. The method is also used

for preventing diabetes and prediabetes and for the treatment of metabolic syndrome and insulin resistance in patients with normal blood pressure. The method involves the combined administration of effective quantities of telmisartan, or a polymorph or salt thereof, and simvastatin. The invention also discloses suitable pharmaceutical compns. containing telmisartan, or a polymorph or salt thereof, and simvastatin, as a combined preparation for simultaneous, sep., or sequential use in the prophylaxis or treatment of the above diseases. Preparation of the sodium salt of telmisartan is described.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:606351 CAPLUS
DOCUMENT NUMBER: 141:134089
TITLE: Telmisartan-atorvastatin combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
INVENTOR(S): Riedel, Axel; Sendra, Josep-Maria; Leiter, Josef M. E.; Kauschke, Stefan; Mark, Michael
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062557	A2	20040729	WO 2004-EP174	20040114
WO 2004062557	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA				
DE 10301371	A1	20040805	DE 2003-10301371	20030116
DE 10335027	A1	20050217	DE 2003-10335027	20030731
AU 2004204352	A1	20040729	AU 2004-204352	20040114
AU 2004204352	B2	20090730		
CA 2513277	A1	20040729	CA 2004-2513277	20040114
US 20040259925	A1	20041223	US 2004-757295	20040114
EP 1587479	A2	20051026	EP 2004-701904	20040114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006455	A	20051206	BR 2004-6455	20040114
CN 1738617	A	20060222	CN 2004-80002407	20040114
JP 2006515614	T	20060601	JP 2006-500557	20040114
AU 2004260606	A1	20050210	AU 2004-260606	20040724
CA 2534006	A1	20050210	CA 2004-2534006	20040724
EP 1651213	A1	20060503	EP 2004-763484	20040724
EP 1651213	B1	20090923		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829511	A	20060906	CN 2004-80022096	20040724
BR 2004013165	A	20061003	BR 2004-13165	20040724
JP 2007500677	T	20070118	JP 2006-521497	20040724
NZ 544877	A	20090430	NZ 2004-544877	20040724
AT 443519	T	20091015	AT 2004-763484	20040724
ZA 2005003542	A	20060726	ZA 2005-3542	20050504

MX 2005007103	A	20050826	MX 2005-7103		20050629
IN 2005DN03073	A	20070112	IN 2005-DN3073		20050711
NO 2005003837	A	20050815	NO 2005-3837		20050815
ZA 2005009835	A	20061129	ZA 2005-9835		20051205
MX 2006001322	A	20060504	MX 2006-1322		20060131
KR 2006054404	A	20060522	KR 2006-702186		20060131
NO 2006000938	A	20060227	NO 2006-938		20060227
PRIORITY APPLN. INFO.:			DE 2003-1030137[1]	A	20030116
			DE 2003-10335027	A	20030731
			US 2003-446695P	P	20030211
			US 2003-503317P	P	20030916
			DE 2003-10346260	A	20031006
			DE 2003-10356815	A	20031205
			WO 2004-EP174	W	20040114
			WO 2004-EP8326	W	20040724

AB The invention discloses a method for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases, achieved by the improvement of endothelial function and the protection of organs, tissues and vessels when indications require a blood pressure check and a lipid level check, especially in patients that have been diagnosed with type 2 diabetes mellitus or if prediabetes is suspected. The method is also used for preventing diabetes and prediabetes and for the treatment of metabolic syndrome and insulin resistance in patients with normal blood pressure. The method involves the combined administration of effective amts. of telmisartan, or a polymorph or salt thereof, and atorvastatin. The invention also discloses suitable pharmaceutical compns. containing telmisartan, or a polymorph or salt thereof, and atorvastatin, as a combined preparation for simultaneous, sep. or sequential use in the prophylaxis or treatment of the above diseases. Preparation of the sodium salt of telmisartan is described.

OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2004:414643 CAPLUS
DOCUMENT NUMBER:	140:412339
TITLE:	Crystalline form of losartan potassium
INVENTOR(S):	Reddy, Manne Satyanarayana; Eswaraiah, Sajja; Koppera, Ravinder Reddy; Reddy, Vajrala Venkata
PATENT ASSIGNEE(S):	Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE:	U.S. Pat. Appl. Publ., 11 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20040097568	A1	20040520	US 2003-629316		20030729
IN 2002MA00568	A	20070727	IN 2002-MA568		20020729
PRIORITY APPLN. INFO.:			IN 2002-MA568	A	20020729

AB A compound that is a crystalline Form III of losartan potassium is provided. Also provided are compns. containing the compound and methods for its preparation For example, 125 g of trityl losartan (preparation given) was mixed with an aqueous solution containing 11 g of KOH, 125 mL water, and 1250 mL methanol until the reaction was complete. The solvent

was distilled off the reaction solution under vacuum, and water (325 mL) added to the residual mass, stirred for 30 min, the pH adjusted to 8.2 to 8.8, and the mass filtered. The filtrate was washed with water, the water was distilled off, and the resulting residue was dissolved in methanol, the solvent distilled off, and the residual mass cooled to a temperature of 5 to 10°, filtered, and dried to yield crystalline polymorph Form III of losartan potassium (weight 43.0 g). The crystalline polymorph Form III of losartan potassium was also obtained from crystalline polymorph Form I of losartan potassium.

```
=>  d his

     (FILE 'HOME' ENTERED AT 15:51:47 ON 26 OCT 2009)

     FILE 'CAPLUS' ENTERED AT 15:52:11 ON 26 OCT 2009
L1          6428 S LOSARTAN
L2            18 S L1 AND "POLYMORPH"
L3             8 S L2 AND COMPOSITION

=> s l1 and stabilizer
         96913 STABILIZER
         75489 STABILIZERS
        129263 STABILIZER
                (STABILIZER OR STABILIZERS)
L4            3 L1 AND STABILIZER

=> d l4 1-3 ibib ab

L4   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2006:699729  CAPLUS
DOCUMENT NUMBER:          145:152705
TITLE:                    Stable noncrystalline formulations comprising
                          losartan
INVENTOR(S):              Palakodaty, Srinivas; Kordikowski, Andreas; Daintree,
                          Linda Sharon; Duddu, Sarma; Kugler, Alan; Zhang,
                          Jiang; Snyder, Herman; Lechuga, David; Palepu, Nagesh;
                          Eldon, Michael A.
PATENT ASSIGNEE(S):       Nektar Therapeutics, USA
SOURCE:                   PCT Int. Appl., 96 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2006076097        A2    20060720    WO 2005-US44278        20051206
     WO 2006076097        A3    20060914
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
```

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20060160871 A1 20060720 US 2005-296108 20051206
PRIORITY APPLN. INFO.: US 2004-633988P P 20041207

AB One or more embodiments of the invention provide various novel formulations, and tablet dosage forms, comprising losartan that are noncryst., stable, and/or otherwise improvements over known losartan formulations. One or more embodiments of the invention further provide methods for preparing the formulation, methods for preparing the tablet dosage form, and to methods of administering the tablet dosage and/or formulation comprising losartan. The losartan -containing formulations may be administered to a user to treat hypertension, and related conditions. A spray drying process is used to produce particles comprising non-crystalline losartan and a stabilizing excipient. The stabilizing excipient comprises a copolymer, such as a vinyl pyrrolidone-vinyl acetate copolymer.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:382957 CAPLUS
DOCUMENT NUMBER: 144:419694
TITLE: Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
INVENTOR(S): Ayres, James W.
PATENT ASSIGNEE(S): State of Oregon Acting by and Through the State Board of Higher Education On Behalf of Oregon State University, USA
SOURCE: PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044202	A2	20060427	WO 2005-US35787	20051003
WO 2006044202	A3	20070301		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1811975	A2	20070801	EP 2005-808429	20051003
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
US 20080020041	A1	20080124	US 2007-665729	20070418
PRIORITY APPLN. INFO.:			US 2004-620482P P	20041019
			WO 2005-US35787 W	20051003

AB Embodiments of a pharmaceutical formulation comprising an enteric material are disclosed. The embodiments release at least a portion of an active ingredient upon contacting gastric fluid. The remaining portion of the formulation releases active ingredient upon contacting intestinal fluid. Certain embodiments of the pharmaceutical composition comprise at least one active ingredient in a core and a leaky enteric coating, such as an enteric coating comprising a gastric fluid channeling agent. Other embodiments of the pharmaceutical composition comprise at least one active ingredient substantially homogeneously admixed with at least one enteric material, such as an enteric material comprising a gastric fluid channeling agent. Disclosed embodiments of the pharmaceutical composition may comprise a single active ingredient, or may comprise plural active ingredients. Generally, but not necessarily, the active ingredient has a window of absorption. The present disclosure also describes a method for treating a subject having a condition treatable by an active ingredient. The method comprises providing one or more embodiments of the pharmaceutical composition disclosed herein comprising an active ingredient suitable for treating the condition. The pharmaceutical composition is administered to the subject. A method for making embodiments of the disclosed composition also is described. The method comprises providing a core comprising an active ingredient. An enteric material is applied to at least a portion of the core, and generally on or about a substantial portion of the core, to form a coat. The composition is then made leaky. For example, hydrochlorothiazide (HCTZ) leaky enteric-coated beads were prepared by spray-layering drug on nonpareil sugar beads and then applying an enteric coating formulated to allow drug to be released in gastric fluid at programmed rates. Hydroxypropylyl Me cellulose (HPMC) was used which allowed drug leakage into gastric fluid and then provided rapid release of remaining drug from the formulation when exposed to intestinal fluid. A leaky enteric-coated bead formulation comprised, e.g., 7.5% of an enteric-coating polymer (Eudragit L30D-55 with 20% HPMC). A HCTZ loading solution contained hydrochlorothiazide 5.0 g, PVP K-30 3.0 g, water 30.0 mL, and 95% ethanol 500.0 mL. A leaky enteric coating composition contained Eudragit L30D-55 58.8%, talc 29.4% and HPMC E5 11.8%.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:154224 CAPLUS
DOCUMENT NUMBER: 138:193294
TITLE: Expandable gastric retention device containing pharmaceutical compositions
INVENTOR(S): Ayres, James W.
PATENT ASSIGNEE(S): The State of Oregon Acting by and Through the State Board of Higher Education On Behalf of Oregon State University, USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015745	A1	20030227	WO 2001-US46146	20011022

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,

US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2456976	A1	20030227	CA 2001-2456976		20011022
AU 2002225872	A1	20030303	AU 2002-225872		20011022
EP 1416914	A1	20040512	EP 2001-995328		20011022

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001017123	A	20040928	BR 2001-17123		20011022
CN 1543337	A	20041103	CN 2001-823544		20011022
JP 2005501097	T	20050113	JP 2003-520705		20011022
NZ 531461	A	20080328	NZ 2001-531461		20011022
NO 2004000611	A	20040416	NO 2004-611		20040211
MX 2004001388	A	20040527	MX 2004-1388		20040213
US 20040219186	A1	20041104	US 2004-778917		20040213
IN 2004KN00232	A	20051230	IN 2004-KN232		20040219
ZA 2004002066	A	20050509	ZA 2004-2066		20040315
PRIORITY APPLN. INFO.:			US 2001-313078P	P	20010816
			WO 2001-US46146	W	20011022

AB The present application concerns gastric retention devices formed from compns. comprising polymeric materials, such as polysaccharides, and optional addnl. materials including excipients, therapeutics, and diagnostics, that reside in the stomach for a controlled and prolonged period of time. Dry powders of xanthan gum and locust bean gum were mixed intimately were converted to dried films. The dried films were compressed with the help of specially made punches and dies. A series of dies with decreasingly narrow internal diams. were used. A punch pushes the film from one die into the next die, followed by pushing of the film by another punch into the next die. This process takes place in succession until a point is reached where the film is small enough to put into a desired capsule size.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT